SOUTH SAN FRANCISCO, Calif., May 31, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2:30pm EDT.
To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate), the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's clinical programs include a Phase 3 study of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) and a Phase 1 study of R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program. In addition, Rigel has product candidates in clinical development with partners BerGenBio ASA, Daiichi Sankyo, Aclaris Therapeutics, and AstraZeneca.
Please see www.TAVALISSE.com for full Prescribing Information.
Contact: David Burke
View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2019-healthcare-conference-300859668.html